Reviews/Motor Neurone Disease Treatment/Non-invasive ventilation prolongs survival
Care · MND-CARE-01 · v2
Across one randomised trial and six separate observational studies, people with motor neurone disease who used non-invasive ventilation tended to live longer than those who did not [1][2][3][4][5][6]. The single randomised trial found a clear survival gain, but only in patients whose speech and swallowing muscles were less affected, and found no survival gain in those with severe bulbar impairment [1]. The observational studies point the same way and show sizeable differences in how long patients survived [2][3][4], yet they cannot rule out that people who took up and tolerated ventilation were already destined to decline more slowly. The panel judged the direction of benefit consistent and independently repeated across countries and decades, which is reassuring. It held back from the top tier because the randomised benefit was limited to one subgroup and the rest of the evidence is observational.
The corpus shows a consistent association between non-invasive ventilation and longer survival in MND/ALS across every study that measured survival [1][2][3][4][5][6]. The one randomised trial reported a median survival benefit of 205 days (p=0.006) in the better-bulbar-function subgroup, with no survival benefit in those with poor bulbar function [1]. Observational cohorts report adjusted hazard ratios favouring ventilation, including 0.72 (0.60 to 0.88) [2] and a protective 0.45 (0.28 to 0.74) for very-early initiation [4], and longer median survival in ventilated patients (40.8 vs 33.6 months) [3]. A post-mortem cohort found a significant survival impact (p=0.01) [6], while [7] measures functional decline rather than survival and so bears on progression indirectly. The contested point: The evidence divides on whether the benefit is unconditional: the only randomised trial restricts the survival gain to the non-bulbar subgroup and finds none in severe bulbar impairment [1], whereas one cohort reports a significant benefit in bulbar-onset patients too [2]. The deeper split is that six of seven papers are observational [2][3][4][5][6][7], so a real causal effect and confounding by indication or healthy-user selection remain difficult to separate.
All 7 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Motor Neurone Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The sole RCT [1] found a survival benefit only in the better-bulbar-function subgroup and explicitly no survival benefit in patients with poor bulbar function, so the unconditional claim overreaches the randomised evidence.
Six of seven papers are observational [2][3][4][5][6][7] and vulnerable to confounding by indication and healthy-user/selection bias: patients who accept and tolerate NIV may have intrinsically slower progression, inflating the apparent survival effect.
Where it remains uncertain. The randomised survival benefit was absent in poor-bulbar-function patients [1], and the corroborating cohorts are observational and open to confounding by indication [2][3][4][5][6].
The load-bearing papers from a corpus of 7, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Randomised evidence of a 205-day survival benefit in patients without severe bulbar dysfunction.
“This subgroup showed improvement in several measures of quality of life and a median survival benefit of 205 days (p=0.006) with maintained quality of life for most of this period.”
Panel auditInternal validity: high · scope of inference: ALS patients reaching respiratory indication for NIV; survival benefit specific to those without severe bulbar dysfunction.Key limitations: small randomised sample · benefit limited to non-severe-bulbar subgroup · no survival benefit in severe bulbar impairment
Large cohort showing a substantial adjusted survival advantage with NIV.
“Median tracheostomy free survival from symptom onset was 28 months in NIV-treated patients compared to 15 months in untreated (Univariate Cox regression HR=0.61 (0.51 to 0.73), p<0.001).”
Panel auditInternal validity: medium · scope of inference: MND/ALS patients at a specialist multidisciplinary clinic initiating NIV per consensus guidelines.Key limitations: observational, non-randomised · indication and selection bias for NIV · single specialist clinic
Real-world register confirming longer survival in NIV-treated patients.
“The median (range) survival was significantly longer in the NIV cohort (40.8 [37.2-44.3] months) and the TIV cohort (82.1 [68.7-95.6] months) as compared to the non-NIV cohort (33.6 [31.6-35.7] months).”
Panel auditInternal validity: medium · scope of inference: ALS patients in a German single-centre register receiving NIV without subsequent tracheostomy.Key limitations: observational, non-randomised · no adjustment reported for the survival comparison · single centre
The abstract reports a slowing of functional decline but provides no survival outcome or comparator from which the claim's direction could be read.
Panel auditInternal validity: medium · scope of inference: ALS patients undergoing NIMV, assessed for rate of non-respiratory functional decline rather than survival.Key limitations: outcome is functional decline, not survival · retrospective design · no survival comparator reported
4 of 7 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, independent evidence anchored by a positive RCT supports the claim, but the subgroup-limited randomised benefit and observational confounding keep it short of Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Survival in poor-bulbar-function patients. The only randomised evidence shows no survival benefit in severe bulbar impairment [1], leaving the claim unsupported for this group. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised or pre-registered prospective trial of non-invasive ventilation powered for survival, stratified by bulbar function.
Open question: Does non-invasive ventilation prolong survival in MND patients with severe bulbar dysfunction? Why it is still open: The only RCT found no survival benefit in this subgroup [1] and cohorts give mixed signals, with one reporting benefit in bulbar onset [2].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19